Reported PL41-PG formulation
| Component | mol% | Role |
|---|
| PL41 | 45 | Ionizable lipid |
| DSPC | 9 | Helper phospholipid |
| Cholesterol | 34.65 | Sterol |
| DMG-PEG2000 | 1.35 | PEG lipid |
| DSPG | 10 | Anionic TREM2 ligand |
Total: 100 mol%. PG denotes 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG). The 5 mol% ligand formulation used PL41:DSPC:cholesterol:DMG-PEG2000:ligand = 47.5:9.5:36.6:1.4:5 mol%. These formulations are distinct from the initial DOPE screening mixture.
Source: Supplementary Table S1 (PDF p. 30 / printed p. 29); main Methods.
Preparation
Microfluidic mixing of aqueous mRNA and ethanol lipid phases at 3:1 by volume. Final mRNA concentration: 0.1 mg/mL. Dialysis overnight at 4 °C against PBS using a 12–14 kDa MWCO membrane. Total mixing flow rate, assembly buffer/pH, N/P and lipid:mRNA mass ratio were not reported in the supplied method.
Source: Methods — Preparation and characterization of LNP formulation (main PDF p. 18).
Experimental evidence
Comparative CAR expression
PL41-PS and PL55-PS were advanced after the healthy-mouse reporter screen (5 µg mRNA per mouse, intraperitoneal, 6 h; n = 5 per group pooled from two experiments). PL41 then gave higher membrane-bound CAR expression than PL55 in mouse BMDM-TAMs and human THP-1-derived M2 macrophages (24 h; n = 3 independent tests).
Source: Main Fig. 2d–g; Supplementary Fig. S6c,d; Methods.
Particle characterization
The tested PL41-PS, PL41-PI and PL41-PG formulations were approximately 150–200 nm and achieved approximately 90% mRNA encapsulation. These ranges describe the tested formulations and are not specifications for neat PL41.
Source: Main text; Supplementary Fig. S6g,h.
TREM2-dependent delivery
In the ligand comparison, the 10 mol% PG formulation gave approximately eightfold higher reporter expression in wild-type than Trem2-knockout macrophages. This comparison is WT versus knockout cells, not PL41 versus ALC-0315.
Source: Main Fig. 2i; main text.
In situ CAR-M and malignant ascites
PL41-PG LNPs delivered hCLDN18.2-targeting CAR mRNA and supported macrophage reprogramming in mouse malignant-ascites models. The study also examined patient-derived ascites ex vivo. Antitumour findings depend on the RNA-loaded formulation, administration schedule, tumour model and, for combination arms, anti-PD-1 treatment.
Source: Main Figs. 3–6; Extended Data; Methods.
Tolerability context
The study evaluated cell viability and mouse tolerability under specified experimental conditions. These preclinical observations do not establish human safety or the safety of other doses, routes or formulations.
Source: Main text and Supplementary Information.
For research use only.